Enlicitide, known during development as MK-0616, is an orally bioavailable macrocyclic peptide that binds circulating PCSK9, the protein that normally marks liver LDL receptors for destruction. By blocking the interaction between PCSK9 and the hepatic LDL receptor, enlicitide prevents receptor degradation and increases receptor recycling to the hepatocyte surface, thereby accelerating clearance of LDL particles from the bloodstream. This mechanism mirrors that of injectable monoclonal antibody PCSK9 inhibitors such as evolocumab and alirocumab, which have already demonstrated major cardiovascular benefit in landmark outcomes trials like FOURIER and ODYSSEY OUTCOMES. The difference is delivery: enlicitide is taken by mouth, potentially sidestepping the cost, access barriers, and needle aversion that have limited broader uptake of injectable agents.

The research team, registered with PROSPERO and conducted according to PRISMA 2020 guidelines, searched PubMed, Embase, Scopus, and ClinicalTrials.gov from inception through March 2026. From 458 initial records, only three trials met the strict eligibility criteria: adults with primary or heterozygous familial hypercholesterolemia and elevated LDL cholesterol despite standard therapy, randomized to enlicitide or placebo. The evidence base comprised the multinational Phase 3 trial by Navar and colleagues enrolling 2909 participants across 14 countries and testing 20 mg once daily for 52 weeks; the Phase 2b dose-ranging trial by Ballantyne and colleagues with 381 participants testing 6, 12, 18, and 30 mg doses over 8 weeks; and a second Phase 3 trial of 303 participants taking 20 mg or placebo for 52 weeks.

The headline result was unambiguous. Across six comparisons from the three trials, enlicitide reduced LDL cholesterol from baseline by a mean difference of 56.19 percent relative to placebo, with a 95 percent confidence interval of 64.14 to 48.25 percent reduction and a p-value below 0.0001. The 95 percent prediction interval, which projects the range of true effects expected in future similar trials, spanned 72.18 to 40.21 percent reduction, meaning a clinically meaningful benefit would be anticipated in essentially any comparable setting. Heterogeneity was moderate at 56.9 percent, and a leave-one-out sensitivity analysis confirmed that no single trial arm drove the overall conclusion.

Dose-response patterns added pharmacological texture to the findings. In the Phase 2b dose-ranging trial, LDL cholesterol reduction was numerically greatest at the 30 mg dose, reaching a mean difference of 60.90 percent, though formal subgroup testing across doses did not reach statistical significance. Importantly, a homogeneity-restricted sensitivity analysis limited to the optimized 20 mg dose at the common 24-week primary endpoint of the two Phase 3 trials, covering 3049 participants, produced an even tighter estimate: a 60.39 percent reduction with a confidence interval of 64.76 to 56.01 percent and zero heterogeneity. Treatment duration also mattered little for the core lipid markers, with no significant difference between 8-week and 52-week comparisons.

The benefits extended well beyond LDL cholesterol alone. Non-HDL cholesterol fell by 51.36 percent, apolipoprotein B by 47.09 percent, and lipoprotein(a) by 20.10 percent, all statistically significant with prediction intervals excluding the null. Triglycerides declined by 13.12 percent, though the prediction interval for that outcome crossed the null, suggesting less consistency. The apolipoprotein B and non-HDL cholesterol reductions are particularly noteworthy because emerging evidence positions these markers as complementary targets that may capture residual atherogenic risk not fully reflected by LDL cholesterol. The lipoprotein(a) finding carries its own intrigue: it was the only outcome showing a duration-related difference, with larger reductions at 52 weeks than at 8 weeks, raising the possibility that this effect deepens with longer exposure, although the authors caution this remains exploratory.

Safety results were broadly reassuring but nuanced. Any adverse event showed a statistically significant but clinically marginal increase with enlicitide, a risk ratio of 1.03 driven overwhelmingly by the largest trial, which contributed 80.4 percent of the pooled weight. More strikingly, serious adverse events were significantly reduced with enlicitide, a risk ratio of 0.84, though the authors urge caution because the prediction interval crossed 1.0 and a single trial supplied 95.7 percent of the weight. Moderate-to-severe adverse events showed no significant difference, and there was a non-significant trend toward fewer treatment discontinuations due to adverse events in the enlicitide group. All-cause mortality was essentially identical between groups. Notably, new-onset or worsening diabetes occurred at comparable rates, and no cases of drug-induced liver injury were reported, consistent with the established safety record of the injectable PCSK9 inhibitor class.

The methodological rigor of the analysis lends weight to its conclusions. The investigators used a random-effects model with restricted maximum-likelihood estimation, applied the conservative Hartung-Knapp adjustment to confidence intervals, and calculated prediction intervals based on the t-distribution. Risk of bias assessment using the Cochrane RoB 2.0 tool rated two trials at low risk overall and one with some concerns, with no trial judged high risk. Certainty of evidence, graded with the GRADE framework, reached moderate for all five lipid outcomes but dropped to low or very low for the safety endpoints, reflecting imprecision and indirectness. The authors also handled a subtle statistical pitfall: because the dose-ranging trial shared a single placebo group across four dose arms, they apportioned the placebo sample size across pairwise comparisons to avoid double-counting, in line with Cochrane Handbook guidance.

Important caveats temper the enthusiasm. All included trials were industry-sponsored, follow-up did not extend beyond 52 weeks, and the entire evidence base rests on surrogate lipid endpoints rather than hard cardiovascular outcomes. The dedicated cardiovascular outcomes trial for enlicitide is still ongoing, and until it reports, the drug’s ability to prevent heart attacks and strokes remains inferred rather than proven. The Phase 3 regimen also required fasting conditions, with participants instructed to take the pill on an empty stomach and avoid food and beverages other than water for 30 minutes afterward. Adherence to both the drug and fasting instructions exceeded 97 percent under controlled trial conditions, but whether such discipline translates to routine clinical practice remains an open question.

Still, the trajectory is familiar and encouraging. Injectable PCSK9 inhibitors followed the same path: robust LDL lowering in surrogate-endpoint trials first, then definitive cardiovascular benefit in large outcomes studies. In the CORALreef Lipids trial, more than 70 percent of participants achieved LDL cholesterol below 70 mg/dL with at least a 50 percent reduction from baseline, and roughly two-thirds reached the more stringent target of below 55 mg/dL. If enlicitide clears its outcomes trial and real-world adherence hurdles, it could reshape the treatment landscape for the substantial proportion of high-risk patients who remain above guideline-recommended LDL targets, offering potent lipid lowering in a form many more patients would actually take.

Subject of Research: Efficacy and safety of the oral PCSK9 inhibitor enlicitide in hypercholesterolemia

Article Title: Efficacy and Safety of Enlicitide in Hypercholesterolemia: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Article References: Farhan, M., Murtaza, M., Rasool, M. M., Khan, F., Amjad, H., Rai, K. D., Ali, S. M. E., Raza, A. A., Sohail, M. A., Samadi, A., & Hassan, F. (2026). Efficacy and Safety of Enlicitide in Hypercholesterolemia: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Endocrinology, Diabetes & Metabolism, 9(6), Article e70358. https://doi.org/10.1002/edm2.70358

Image Credits: AI Generated

DOI: 10.1002/edm2.70358

Keywords: enlicitide, PCSK9 inhibitor, LDL cholesterol, hypercholesterolemia, meta-analysis, cardiovascular disease, apolipoprotein B, lipoprotein(a), statins, oral peptide drug, lipid-lowering therapy, randomized controlled trials